BioCentury
ARTICLE | Clinical News

GR-MD-02: Ph IIa data

March 17, 2017 1:01 PM UTC

Data from 5 patients with moderate to severe plaque psoriasis in an open-label, U.S Phase IIa trial showed that 8 mg/kg IV GR-MD-02 every other week led to an average reduction in PASI score of >50% a...

BCIQ Company Profiles

Galectin Therapeutics Inc.

BCIQ Target Profiles

Galectin-3 (LGALS3)